英语释义

• an inactive form of plasmin that occurs in plasma and is converted to plasmin by organic solvents

片语

plasminogen inhibitors纤溶酶原灭活剂

plasminogen activator inhibitor纤溶酶原激活物抑制剂

Plasminogen Inactivators纤溶酶原灭活剂

plasminogen activity纤溶酶原活性

plasminogen activator[生化] 纤溶酶原激活物；胞浆素原活化体（等于urokinase）

plasminogen active纤溶活化

plasminogen kringle纤溶酶原kringle5功能区

plasminogen activation纤溶酶原激活

type plasminogen纤溶酶原

urinary plasminogen尿激酶型纤溶酶型激活因子

英汉例句

• objective to observe the effect of recombinant tissue plasminogen activator in the treatment of acute myocardial infarction.

  目的观察应用重组组织型纤溶酶原激活剂溶栓治疗急性心肌梗死的效果。

• objective to explore the relationship between the activity change of tissue type plasminogen activator(tpa) of retinas and retinal edema in retinal ischemia and reperfusion rats.

  目的探讨缺血-再灌注对大鼠视网膜分泌组织型纤溶酶原激活物（tpa）的影响及其与视网膜水肿的关系。

• objective to study the effects of transient cerebral ischemic reperfusion(ir) and flunarizine on the expression of plasminogen activator inhibitor-1(pai-1) protein in brain tissue of gerbils.

  目的研究沙鼠脑缺血再灌注后脑内1型纤溶酶原激活物抑制剂（pai-1）蛋白表达变化，以及西比灵干预的影响。

• objective to study the relationship of plasminogen activator inhibitor type 1(pai 1) to platelet activity in elderly patients with unstable angina pectoris(uap).

  目的探讨老年不稳定型心绞痛（uap）与纤溶酶原激活物抑制剂1型（pai1）及血小板活化功能的临床意义。

• objective to study the changes of the endothelial tissue plasminogen activator reserve capacity in patients with acute coronary syndromes.

  目的探讨急性冠状动脉综合征患者内皮组织纤溶酶原激活剂储备功能的变化规律。

• objective: to evaluate the efficacy and safety of recombinant tissue plasminogen activator in hyper acute cerebral infarction.

  目的：评价重组组织型纤溶酶原激活剂治疗急性脑梗死的疗效及安全性。

• recently, a lot of studies have been demonstrated that spc increased cell migration and induced the expression of plasminogen activator related to cell migration.

  最近发现spc促进细胞的移动，诱导成纤维细胞表达与细胞移动有关的血纤维蛋白溶酶原激活剂。

• hmgb1 plays roles in activation of plasminogen and matrix metalloproteases, reorganization of cytoskeleton.

  hmgb1与纤维蛋白酶原、基质金属蛋白酶的活化、细胞骨架重组等有关。

• objective to investigate effects of two proinflammatory cytokines on the production of plasminogen activator inhibitor 1(pai 1) by human pleural mesothelial cells(hpmc).

  目的研究前炎癥细胞因子对人胸膜间皮细胞（hpmc）释放纤溶酶原激活物抑制剂（pai1）的诱导效应。

• objective to construct an expression vector for highly efficient expression of tissue-type plasminogen activator (t-pa) confined in the mammary gland of cow to develop a cow mammary gland bioreactor.

  目的构建组织型纤溶酶原激活剂（t-pa）乳腺定位表达载体，使其在牛乳汁中高效表达，从而建立牛乳腺生物反应器。

• objective to monitor the dynamic changes of tissue type plasminogen activator(t-pa) and plasminogen activator inhibitor-i(pai-i) activity after and before ptca in patients with acs.

  目的观察急性冠脉综合征（acs）患者冠脉成形术（ptca）前后血浆组织型纤溶酶原激活物（t-pa）及纤溶酶原激活抑制剂（pai-i）的动态变化。

• the researchers also found that plasminogen activator inhibitor type 2 (pai2), a serine-protease inhibitor, inhibited proteolytic truncation of annexin-1 in macrophages infected with m. tuberculosis.

  研究者还发现2型纤维蛋白溶酶原激活因子抑制物（pai2）（一种丝氨酸蛋白酶抑制物）抑制结核桿菌感染的巨噬细胞内的膜联蛋白-1的蛋白水解作用。

• nihss scores were determined before tissue plasminogen activator bolus and at 60 and 120 minutes in both data sets.

  在两个试验中，在组织纤维蛋白溶酶原激活剂使用前，都先用nihss评分。

• lysis of the hematoma with various enzymes, such as urokinase or tissue plasminogen activator (tpa), and drainage of liquefied clot has become an alternative.

  因而，应用不同的酶如尿激酶或组织纤维蛋白溶酶原激活剂来溶解血肿和引流液化的血凝块，成为可供选择的治疗方法。

• urokinase, a human plasminogen activator, is used clinically to promote the dissolution of thrombi.

  尿激酶是一种纤溶酶原激活剂，临床上用于治疗血栓。

• objective to investigate the plasma tissue-type plasminogen activator(t-pa) and plasminogen activator inhibitor(pai) in coronary heart disease patients with angina pectoris and its probable mechanism.

  目的探讨冠心病心绞痛病人血浆组织型纤溶酶原激活物（tpa）及其抑制物（pai）活性的变化及其可能机制。

• this was accompanied by severe disruption of the blood–brain barrier and an increased rate of intracerebral hemorrhages after tissue plasminogen activator treatment.

  这一现象伴随血脑屏障的严重破坏和组织型纤维蛋白溶酶原激活剂治疗后的脑出血率增加。

• objective to explore the relationship between plasminogen activator inhibitor type-1 (pai-1)and its biological behaviour of hepatocellular carcinoma (hcc).

  目的研究纤溶酶原激活物抑制剂（pai-1）与肝癌临床生物学特性的关系。

• objectivesto study the change of plasminogen activation system in different behavior type patients with coronary heart disease.

  目的研究不同行为类型冠心病患者之间纤溶激活系统的变化。

• the von willebrand's disease factors in plasm, adjusted protein of thrombase and inhibitor 1 of activator of plasminogen were detected with enzyme-linked immunosorbent assay.

  用酶联免疫吸附法检测血浆血管性假性血友病因子、凝血酶调节蛋白、纤溶酶原激活物抑制物1水平。

• plasminogen activators are widely used as thrombolytic drugs clinically, while they are far away from perfect and urgent requests call for development of new thrombolytic drugs.

  已临床使用的溶栓药物主要是纤溶酶原激活剂类，但还存在许多缺陷，因此新型溶栓药物的研制迫在眉睫。

• reciprocal activation of prourokinase and plasminogen is an important mechanism in the initiation and propagation of local fibrinolytic activity.

  纤溶酶原和尿激酶前体的相互活化作用在纤溶的开始和加速上发挥着重要的作用。

• objective to study the expression of plasminogen activator inhibitor-1(pai-1) of the blood serum and plaques in atherosclerotic rabbits in order to explore the effect of pai-1 on atherosclerosis (as).

  目的通过对动脉粥样硬化（as）兔血清和粥样硬化斑块中纤溶酶原激活物抑制物-1（pai-1）表达的研究，探讨pai-1在as中的作用。

• objective to investigate the relationship between the plasminogen activator inhibitor 1(pai 1) promotor region gene polymorphism and cerebral stroke.

  目的探讨纤溶酶原激活物抑制物- 1（pai-1）启动子区基因多态性与脑卒中的关系。

• objectiveto study the role and significance of plasminogen activator inhibitor-1(pai-1) in renal fibrosis(rf) after damage and elucidate the molecular pathogenetic mechanisms of rf.

  为探讨纤溶酶原激活物抑制因子1（pai1）在肾损伤后纤维化中的作用和意义，揭示其发病的分子病理机制。